Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors

Mohammad A. Khanfar, Luisa Quinti, Hua Wang, Johnathan Nobles, Aleksey G. Kazantsev, Richard B. Silverman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Inhibitors of sirtuin-2 (SIRT2) deacetylase have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the 3-(benzylsulfonamido)benzamide scaffold and improving their metabolic stability. Molecular modeling and docking studies revealed an unfavorable role of the sulfonamide moiety for SIRT2 binding. This prompted us to replace the sulfonamide with thioether, sulfoxide, or sulfone groups. The thioether analogues were the most potent SIRT2 inhibitors with a two- to three-fold increase in potency relative to their corresponding sulfonamide analogues. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. Two thioether-derived compounds (17 and 18) increased α-tubulin acetylation in a dose-dependent manner in at least one neuronal cell line, and 18 was found to inhibit polyglutamine aggregation in PC12 cells.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume6
Issue number5
DOIs
StatePublished - May 14 2015
Externally publishedYes

Fingerprint

Sirtuin 2
Derivatives
Sulfonamides
Sulfides
sulfoxide
Huntington Disease
Agglomeration
Acetylation
Sulfones
Molecular modeling
PC12 Cells
Pathology
Tubulin
Scaffolds
Cells
benzamide
Cell Line

Keywords

  • 3-(benzylthio)benzamide
  • docking
  • Huntington's disease
  • polyglutamine aggregation
  • SIRT2

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors. / Khanfar, Mohammad A.; Quinti, Luisa; Wang, Hua; Nobles, Johnathan; Kazantsev, Aleksey G.; Silverman, Richard B.

In: ACS Medicinal Chemistry Letters, Vol. 6, No. 5, 14.05.2015, p. 607-611.

Research output: Contribution to journalArticle

Khanfar, Mohammad A. ; Quinti, Luisa ; Wang, Hua ; Nobles, Johnathan ; Kazantsev, Aleksey G. ; Silverman, Richard B. / Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors. In: ACS Medicinal Chemistry Letters. 2015 ; Vol. 6, No. 5. pp. 607-611.
@article{ae472ddf7d9b4ae7bd5562fd267eb009,
title = "Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors",
abstract = "Inhibitors of sirtuin-2 (SIRT2) deacetylase have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the 3-(benzylsulfonamido)benzamide scaffold and improving their metabolic stability. Molecular modeling and docking studies revealed an unfavorable role of the sulfonamide moiety for SIRT2 binding. This prompted us to replace the sulfonamide with thioether, sulfoxide, or sulfone groups. The thioether analogues were the most potent SIRT2 inhibitors with a two- to three-fold increase in potency relative to their corresponding sulfonamide analogues. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. Two thioether-derived compounds (17 and 18) increased α-tubulin acetylation in a dose-dependent manner in at least one neuronal cell line, and 18 was found to inhibit polyglutamine aggregation in PC12 cells.",
keywords = "3-(benzylthio)benzamide, docking, Huntington's disease, polyglutamine aggregation, SIRT2",
author = "Khanfar, {Mohammad A.} and Luisa Quinti and Hua Wang and Johnathan Nobles and Kazantsev, {Aleksey G.} and Silverman, {Richard B.}",
year = "2015",
month = "5",
day = "14",
doi = "10.1021/acsmedchemlett.5b00075",
language = "English (US)",
volume = "6",
pages = "607--611",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIRT2 inhibitors

AU - Khanfar, Mohammad A.

AU - Quinti, Luisa

AU - Wang, Hua

AU - Nobles, Johnathan

AU - Kazantsev, Aleksey G.

AU - Silverman, Richard B.

PY - 2015/5/14

Y1 - 2015/5/14

N2 - Inhibitors of sirtuin-2 (SIRT2) deacetylase have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the 3-(benzylsulfonamido)benzamide scaffold and improving their metabolic stability. Molecular modeling and docking studies revealed an unfavorable role of the sulfonamide moiety for SIRT2 binding. This prompted us to replace the sulfonamide with thioether, sulfoxide, or sulfone groups. The thioether analogues were the most potent SIRT2 inhibitors with a two- to three-fold increase in potency relative to their corresponding sulfonamide analogues. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. Two thioether-derived compounds (17 and 18) increased α-tubulin acetylation in a dose-dependent manner in at least one neuronal cell line, and 18 was found to inhibit polyglutamine aggregation in PC12 cells.

AB - Inhibitors of sirtuin-2 (SIRT2) deacetylase have been shown to be protective in various models of Huntington's disease (HD) by decreasing polyglutamine aggregation, a hallmark of HD pathology. The present study was directed at optimizing the potency of SIRT2 inhibitors containing the 3-(benzylsulfonamido)benzamide scaffold and improving their metabolic stability. Molecular modeling and docking studies revealed an unfavorable role of the sulfonamide moiety for SIRT2 binding. This prompted us to replace the sulfonamide with thioether, sulfoxide, or sulfone groups. The thioether analogues were the most potent SIRT2 inhibitors with a two- to three-fold increase in potency relative to their corresponding sulfonamide analogues. The newly synthesized compounds also demonstrated higher SIRT2 selectivity over SIRT1 and SIRT3. Two thioether-derived compounds (17 and 18) increased α-tubulin acetylation in a dose-dependent manner in at least one neuronal cell line, and 18 was found to inhibit polyglutamine aggregation in PC12 cells.

KW - 3-(benzylthio)benzamide

KW - docking

KW - Huntington's disease

KW - polyglutamine aggregation

KW - SIRT2

UR - http://www.scopus.com/inward/record.url?scp=84929323269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929323269&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.5b00075

DO - 10.1021/acsmedchemlett.5b00075

M3 - Article

VL - 6

SP - 607

EP - 611

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 5

ER -